Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

165P - Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first line immunotherapy-based regimens


03 Apr 2022


Poster Display session


Immunotherapy;  Translational Research

Tumour Site

Non-Small Cell Lung Cancer


Giulia Mazzaschi


Annals of Oncology (2022) 33 (suppl_2): S105-S110. 10.1016/annonc/annonc865


G. Mazzaschi1, M. Verzè1, D. Tognazzi1, B. Lorusso1, R. Minari2, M. Pluchino1, F. Trentini1, M. Manini2, P. Bordi2, A. Leonetti2, F. Perrone2, M. Corianò1, M. Casali3, I. Toscani4, A. Cosenza1, L. Ferri1, S. Buti1, N. Sverzellati5, F. Quaini6, M. Tiseo1

Author affiliations

  • 1 University Hospital of Parma, Medical Oncology Unit, Parma/IT
  • 2 University Hospital of Parma, Medical Oncology Unit, 43126 - Parma/IT
  • 3 AOU Integrata di Verona - Ospedale Borgo Roma, Verona/IT
  • 4 Azienda Ospedaliera Piacenza, 29121 - Piacenza/IT
  • 5 University Hospital of Parma, Radiological Science, 43126 - Parma/IT
  • 6 University Hospital of Parma, Parma/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 165P


The groundbreaking results of Immune Checkpoint Inhibitors (ICIs) in NSCLC still involve a limited subset of cases, thus imposing an optimization of patient selection. With the aim to non-invasively intercept tumor-host events implicated in cancer immune surveillance and response to immunotherapy, we explored the dynamic of blood immune-inflammatory markers in a cohort of advanced NSCLC treated with first-line ICIs.


Peripheral blood was prospectively collected at baseline (T0) and at first radiological disease assessment (T1) from 47 consecutive NSCLC patients undergoing first-line ICI-based therapy. We performed a flow-cytometric analysis of circulating CD3+, CD8+, CD4+, NK, NKT and Tregs as their expression of functional molecules (PD-1, Granzyme B [GnzB], Perforin [Perf]) and proliferative index (Ki67). Soluble PD-L1 (sPD-L1) was determined by immunoassay together with Lung Immune Prognostic Index (LIPI: LDH + derived Neutrophil-to-Lymphocyte Ratio). All these parameters were correlated to objective response rate (ORR) according to RECIST v1.1 criteria.


From October 2020 to August 2021, 47 advanced NSCLC patients candidate to receive first-line ICI-based therapy were enrolled. Median age was 67.8 years (range 41-82), 66% were males and 81% underwent chemo-immunotherapy. ORR resulted 51%. Among baseline parameters, number of metastatic sites, bone lesions and poor LIPI negatively correlated with ORR (p<0.05), while a trend towards favorable response was apparent in tissue PD-L1high cases (ORR=67% vs 28% in PD-L1neg). A significant proliferative burst of CD8+PD-1+ lymphocytes carrying cytotoxic molecules (GnzB+, Perf+) coupled with sPD-L1 decline characterized responders. Conversely, CD8+ GnzB+/Perf+ and NK cells dramatically dropped in non-responders (χ2 test, p<0.01). Furthermore, the kinetic and extent of Treg counteraction, likely triggered by the expanding (Ki67+) pool of effector lymphocytes, appeared to be a distinctive feature of responsive patients.


Our results suggest that tracking the evolution of blood immune-inflammatory profiles may provide valuable predictors of ICI efficacy in NSCLC patients.

Legal entity responsible for the study

University Hospital of Parma.


Associazione Italiana per la Ricerca sul Cancro-AIRC.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.